SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-018321
Filing Date
2021-03-29
Accepted
2021-03-29 16:46:27
Documents
3
Period of Report
2021-03-29
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea138509-8k_geminitherap.htm 8-K 19920
2 PRESS RELEASE BY GEMINI THERAPEUTICS, INC., DATED MARCH 29, 2021 ea138509ex99-1_geminitherap.htm EX-99.1 38125
3 GRAPHIC ex99-1_001.jpg GRAPHIC 11792
  Complete submission text file 0001213900-21-018321.txt   75653
Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Gemini Therapeutics, Inc. /DE (Filer) CIK: 0001816736 (see all company filings)

IRS No.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39438 | Film No.: 21782222
SIC: 2834 Pharmaceutical Preparations